关注
Ramya Thota
Ramya Thota
Intermountain Healthcare
没有经过验证的电子邮件地址
标题
引用次数
引用次数
年份
Treatment of metastatic pancreatic adenocarcinoma: a review
R Thota, JM Pauff, JD Berlin
Oncology (Williston Park) 28 (1), 70-4, 2014
1942014
Barriers and facilitators to telemedicine: can you hear me now?
AM Lopez, K Lam, R Thota
American Society of Clinical Oncology educational book. American Society of …, 2021
1412021
Patterns of chemotherapy‐associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study
E Culakova, R Thota, MS Poniewierski, NM Kuderer, AF Wogu, DC Dale, ...
Cancer medicine 3 (2), 434-444, 2014
1252014
Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran's Affairs cancer population
WI Gonsalves, T Tashi, J Krishnamurthy, T Davies, S Ortman, R Thota, ...
Journal of palliative medicine 14 (11), 1231-1235, 2011
1022011
American Society of Clinical Oncology road to recovery report: learning from the COVID-19 experience to improve clinical research and cancer care
NA Pennell, M Dillmon, LA Levit, EA Moushey, AS Alva, S Blau, ...
Journal of Clinical Oncology 39 (2), 155-169, 2021
942021
Clinicopathological features and survival outcomes of primary signet ring cell and mucinous adenocarcinoma of colon: retrospective analysis of VACCR database
R Thota, X Fang, S Subbiah
Journal of gastrointestinal oncology 5 (1), 18, 2014
802014
Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
ER Ahn, PK Mangat, E Garrett-Mayer, S Halabi, EG Dib, DE Haggstrom, ...
JCO precision oncology 4, 757-766, 2020
682020
Immune-mediated complications after hematopoietic stem cell transplantation
Z Li, SM Rubinstein, R Thota, M Savani, E Brissot, BE Shaw, NS Majhail, ...
Biology of Blood and Marrow Transplantation 22 (8), 1368-1375, 2016
682016
Telehealth is a sustainable population health strategy to lower costs and increase quality of health care in rural Utah
R Thota, DM Gill, JL Brant, TJ Yeatman, DS Haslem
JCO Oncology Practice 16 (7), e557-e562, 2020
492020
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
B Sangro, SL Chan, RK Kelley, G Lau, M Kudo, W Sukeepaisarnjaroen, ...
Annals of Oncology 35 (5), 448-457, 2024
402024
An update on gastric cancer
SA Ahmad, BT Xia, CE Bailey, DE Abbott, BA Helmink, MC Daly, R Thota, ...
Current problems in surgery 53 (10), 449-490, 2016
402016
Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: a Veterans' Affairs Central Cancer Registry (VACCR) database analysis
WI Gonsalves, S Kanuri, T Tashi, I Aldoss, A Sama, I Al‐Howaidi, A Ganta, ...
Journal of Surgical Oncology 104 (6), 667-671, 2011
402011
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted …
JG Fisher, D Tait, E Garrett-Mayer, S Halabi, PK Mangat, JC Schink, ...
Targeted oncology 15, 733-741, 2020
392020
Trametinib in the treatment of melanoma
R Thota, DB Johnson, JA Sosman
Expert opinion on biological therapy 15 (5), 735-747, 2015
352015
Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma?
R Thota, RS Gonzalez, J Berlin, DB Cardin, C Shi
American Journal of Clinical Pathology 148 (3), 208-214, 2017
312017
Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels
R Thota, AK Ganti, S Subbiah
Journal of thrombosis and thrombolysis 34, 132-134, 2012
292012
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR …
KA Klute, M Rothe, E Garrett-Mayer, PK Mangat, R Nazemzadeh, KJ Yost, ...
JCO precision oncology 6, e2200191, 2022
242022
Pembrolizumab in patients with tumors with high tumor mutational burden: results from the targeted agent and profiling utilization registry study
HL Duvivier, M Rothe, PK Mangat, E Garrett-Mayer, ER Ahn, ...
Journal of Clinical Oncology 41 (33), 5140-5150, 2023
202023
A phase II study of ganetespib as second-line or third-line therapy for metastatic pancreatic cancer
DB Cardin, R Thota, LW Goff, JD Berlin, CM Jones, GD Ayers, ...
American journal of clinical oncology 41 (8), 772-776, 2018
182018
Preclinical rationale for the phase III trials in metastatic pancreatic cancer: is wishful thinking clouding successful drug development for pancreatic cancer?
R Thota, A Maitra, JD Berlin
Pancreas 46 (2), 143-150, 2017
162017
系统目前无法执行此操作,请稍后再试。
文章 1–20